Plan B (Levonorgestrel)
PreclinicalSmall molecule
Plan B (Levonorgestrel) is one of 16 small molecule programs targeting Female. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Female
#DrugCompanyPhaseTrials
1Activella
Eli LillyApproved
Dostarlimab
IncytePhase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Versed
CConrado Roberto Hoffmann Filho
Phase 1
Faslodex
FFresenius Kabi USA, LLC
Phase 1
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
MK-8527
Merck & Co.Phase 1
Telpegfilgrastim
XXiamen Amoytop Biotech Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Plan B (Levonorgestrel). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pennsylvania